Key Highlights

  • CELU was down 8.64 percent at USD 0.7310 in pre-market trading on November 2, 2026.
  • The company regained Nasdaq periodic reporting compliance on October 22, 2026.
  • A Recapitalization first closing raised over USD 10 million in gross proceeds on September 24, 2026.
  • The full plan contemplates up to USD 25 million of new cash.
  • Notes convert at USD 1.50 per share initially, well above the pre-market price.

What moved the stock in pre-market trading

Celularity (NASDAQ:CELU) was down 8.64 percent at USD 0.7310 in pre-market trading on November 2, 2026. No company announcement dated November 2, 2026 was identified.

The shares have swung widely in recent months, including large gains around late August, so profit taking after a volatile run is one plausible factor, though that is an inference and not a company statement. The pre-market price also sits below the initial note conversion price of USD 1.50 per share, calculated at roughly half of that level.

The Nasdaq compliance update

According to a company press release dated October 22, 2026, Celularity regained compliance with Nasdaq's periodic reporting rule after filing its Quarterly Report for the period ended June 30, 2026 on October 20, 2026. The company said all three disclosed deficiencies were now closed and that it is rebuilding its finance team.

Nasdaq had notified the company on August 21, 2026 that the quarterly reports for March 31 and June 30, 2026 were not filed. A compliance plan was due September 4, 2026, and any exception could run no later than November 16, 2026.

Business background and recent updates

Celularity is a cell and regenerative medicine company. On August 27, 2026 it announced a Manufacturing collaboration to produce Dezawa MuseCell at its Florham Park, New Jersey site. The partner projected more than USD 300 million in aggregate purchases over five years.

In June 2026 the company said it out-licensed its biomaterials Business for up to USD 30 million, eliminating about USD 13 million of recorded liabilities.

Balance sheet and risks

The September 24, 2026 recapitalization carries notes with 10 percent interest, a 24-month Maturity and an initial conversion price of USD 1.50 per share. The company said monthly cash burn fell by more than USD 1 million and it expects positive Operating Cash Flow by the end of the first quarter of 2027. Later closings are not assured.

As a penny stock, CELU can be volatile with thin liquidity, and note conversions or additional raises could dilute shareholders.

What to watch next

Investors will look for the quarter ended September 30, 2026 filing and timely compliance, further closings of the recapitalization and progress on the manufacturing collaboration.

Updates on cash burn against the stated first quarter 2027 target will also help judge the turnaround plan. A clean, on-time filing record would address the reporting gaps that triggered the August notice.